IPO8

Across TCGA pan-cancer cohorts, IPO8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated IPO8 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IPO8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IPO8 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

LIHC, UCEC, and LUSC are the cancer types where IPO8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.104	0.779	<.001	42	view →
UCEC	DFS	Median	II,III,IV	0.936	0.431	.010	24	view →
LUSC	OS	Median	III,IV	0.147	0.664	.028	12	view →
STAD	DFS	Median	IV	1.000	0.284	.038	2	view →
COAD	DFS	Median	All	1.000	0.776	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

IPO8–LIHC (OS)

Open the LIHC breakdown →